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Abstract
Background and purpose: Nicotinamide was administered daily as a liquid formulation to head and neck cancer patients receiving a 5- 
to 7-week course of radiotherapy. The pharmacokinetics, compliance, and tolerance of this drug formulation were studied.
M aterials and methods: Blood samples were drawn and nicotinamide levels determined in 40 head and neck cancer patients. On the 
first treatment day serial samples were obtained followed by daily samples at the time of irradiation during the first and last full weeks of 
the treatment. Side-effects of nicotinamide were monitored.
Results: In all patients peak concentrations greater than 700 nmol/ml could be obtained 0.25-3 h (mean 0.83 ± 0.73 h) after drug 
intake. During the first week of treatment plasma levels at the time of irradiation were adequate in 82% of the samples. This decreased to 
59% in the last week of treatment which can be partly attributed to reduced compliance. The most important side-effect o f nicotinamide 
was nausea with or without vomiting occurring in 65% of the patients. Severe side-effects were associated with high plasma concen­
trations over subsequent days. Tolerance improved after a 25% reduction of dose in six of seven patients but plasma levels at the time o f  
irradiation fell below 700 nmol/ml in four out of six o f  these patients.
Conclusions: Peak plasma concentrations above the 700 nmol/ml level were obtained in all patients but these concentrations could not 
be reproduced during the entire course of the treatment in a significant portion of the subjects. Side-effects of nicotinamide are 
associated with plasma concentrations and tolerance can be improved by a moderate reduction of dose. © 1997 Elsevier Science
B.V. All rights reserved
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1. Introduction
Nicotinamide is currently being assessed in clinical 
trials as a modifier of acute perfusion-limited tumour- 
hypoxia. This compound can reduce the intermittent clo­
sure of blood vessels in experimental rodent tumours [2,7] 
and consequently decrease hypoxic-cell radioresistance 
[6,10], In addition, nicotinamide has been shown to 
enhance the sensitising effect of carbogen [1,12,13], 
which overcomes the sparing effect of chronic diffusion- 
limited hypoxia [16]. With fractionated radiation sche­
dules to mouse tumours, relative to radiation treatments
* Corresponding author.
in air without the drug, enhancement ratios in the order of 
1.3-1.9 have been obtained for the combination of carbo­
gen and nicotinamide [3,12,14,15], Experimentally, 
plasma levels of 700 nmol/ml of nicotinamide are required 
at the time of irradiation to obtain a sensitising effect 
[8,15], Initial studies in healthy human volunteers showed 
that peak plasma levels of 800-1600 nmol/ml could be 
obtained after oral intake of 6 g [8,19]. Horsman et al. 
showed that for maximal radiosensitization tumours 
should be inradiated at the time of peak drug levels [8].
The current clinical practice is to prescribe the drug on a 
weight adjusted basis and adequate plasma levels can be 
obtained in patients with oral doses of 80 mg/kg/d ay 
[9,18]. In a recent study performed on a small number of
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patients undergoing CHART and given this dose of nico­
tinamide over 12 consecutive days, the drug was well 
tolerated but large inter-patient variations were seen both 
with regards to the maximum plasma concentration (Cmax) 
obtained and the time taken to reach this peak (!Tmax). Peak 
levels were reported to range from 400 to 1400 nmol/ml 
with Tmm values from 0.8 to 4 h, but in the four patients in 
which repeated assessments were made at various times 
during the course of radiotherapy the kinetic parameters 
were reproducible [9]. However, there are no reliable phar­
macokinetic and toxicity data with prolonged daily admin­
istration of high doses of nicotinamide during a 5- to 7- 
week course of radiotherapy and information on patient 
compliance is also lacking.
Although nicotinamide was suggested as a relatively 
non-toxic agent with a low incidence of side-effects even 
at the dose levels required for tumour radiosensitization 
[20], in our experience gastrointestinal complaints occur 
frequently. In a previous study 60% and 36% of the 
patients had nausea and vomiting respectively and in 
26% this was reason to discontinue drug intake [11]. Till 
now clinical studies have failed to demonstrate a relation­
ship between side-effects and nicotinamide plasma levels 
[18].
We therefore decided to investigate if adequate nicoti­
namide plasma levels could be obtained in head and neck 
cancer patients enrolled in a study combining radiotherapy 
with carbogen breathing and nicotinamide and whether 
such levels were maintained throughout the course of 
treatment. We also aimed to study whether the use of a 
liquid formulation of the drug improves the pharmacoki­
netic parameters of Cmax and/or Tmax and whether there is a 
relationship between plasma levels and the incidence and 
severity of toxic side-effects. This paper reports on data 
obtained in 40 patients undergoing either conventional or 
accelerated radiotherapy.
2. Materials and methods
2.1. Patients
In our institute head and neck cancer patients with Stage 
III—IV disease and also Stage II hypopharyngeal cancer 
are currently being enrolled in a study combining radio­
therapy with carbogen breathing and nicotinamide, details 
of which have been described previously [11], Inclusion 
criteria are: age over 18 years, WHO performance status of 
0-2, no severe heart or lung disease, no severe liver or 
kidney dysfunction, no severe stridor, no distant metas- 
tases, and written informed consent. From February 
1995 to March 1996, after approval from the local ethical 
committee, 40 consecutive patients consented to have 
plasma samples drawn for determination of nicotinamide 
levels. There were 28 men and 12 women. Mean age was 
61 years with a range of 41-82 years.
2.2. Radiotherapy
Nine patients were treated by a conventional schedule 
and 31 by an accelerated fractionation schedule. Conven­
tional radiotherapy was given in fractions of 2 Gy, five 
times a week to a total dose of 68 Gy. Overall treatment 
time was 46-48 days. With the accelerated schedule the 
total dose was 64-68 Gy while dose per fraction remained 
the same and treatment time was reduced by 10 days by 
giving two fractions per day during the last 1.5 weeks of 
the treatment. The interval between the two fractions per 
day was 6 h. Some patients were hospitalised when they 
were treated twice daily because of travelling distance.
2.3. Nicotinam icle adm in is trat ion
Nicotinamide (Pharmachemie, Haarlem, The Nether­
lands), dissolved in fruit juice was administered orally 
1.5 h before irradiation. After the pharmacokinetic data 
of the first 22 patients were analysed, the interval was 
changed to 1 h for the following 18 patients. A light 
meal, if taken at least 1 h before drug intake, was allowed, 
On days when two fractions were given, only one dose of 
nicotinamide was administered before the first treatment. 
The daily dose was 80 mg/kg to a maximum of 6 g. Since 
November 1995 a dose reduction to 60 mg/kg was intro­
duced for patients with severe side-effects, Sixteen 
patients have been treated with this approach. If a dose 
reduction was applied, nicotinamide was discontinued dur­
ing one day prior to this to allow complete elimination of 
the drug in case accumulation had occurred.
2.4. Sample acquisition and analysis o f nicotinamide
concentrations
On the first treatment day serial samples were taken 
usually through an intravenous cannula inserted in the 
arm. An initial 5 ml of blood was discarded before the 
actual sample was collected. On subsequent days blood 
was drawn by way of a venous puncture. Five-ml samples 
were collected in heparinized tubes and immediately 
stored at 4°C. Plasma was separated by centrifugation 
(3000 x g\ 10 min) within 8 h of sampling and then stored 
at -20°C prior to analysis. Nicotinamide concentrations 
were determined in methanol extracts of plasma using 
high performance liquid chromatography [17]. From all 
patients a full profile was obtained on the first day of 
treatment. Sampling times on the first day were at 0, 
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 12 h after nicotinamide 
ingestion and the residual level was measured after 24 h 
(Cres). One or 1.5 h after intake of the second dose another 
sample was collected. Because of the frequent sampling on 
these first 2 days, patients were hospitalised during this 
time. Thereafter samples were obtained daily during the 
first and last full weeks of the treatment at the time of 
irradiation, i.e. 1 or 1.5 h after nicotinamide intake. In
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addition, if nicotinamide dose was reduced, plasma sam- 
pies were collected on at least 3 consecutive days starting 
on the first day of dose reduction.
2.5. Monitoring during treatment
At each time of sampling blood pressure and heart rate 
were recorded. During the course of treatment the patients 
were seen by both the attending radiotherapist and, sepa­
rately, by the research assistant at least once a week and 
more frequently if necessary, e.g. when side-effects 
occurred. Patients were asked if any adverse events had 
occurred and they were specifically asked if they had 
experienced nausea and/or vomiting. If they reported 
vomiting they were asked to specify when this occurred 
and how often. Anti-emetics (metoclopramide, ondanse­
tron) were prescribed when necessary. Side-effects of 
nicotinamide were considered severe if they led to a dis­
continuation of the drug or a reduction of the daily dose. 
Gastrointestinal bleeding in one patient and renal dysfunc­
tion in another patient were felt to be possibly related to 
nicotinamide and also scored as severe.
2.6. Statistics
For each patient the plasma levels obtained at the time 
of irradiation during the first full week were plotted and a 
lineal' least-squares regression fit was done. If there was a 
positive and significant (P <  0.05) correlation of plasma 
levels with time, the patient was considered to accumulate 
nicotinamide with daily administration. A discriminant 
analysis was done to examine which pharmacokinetic 
parameters predicted best for nicotinamide toxicity* All 
statistical analyses were done on a Macintosh computer 
using the Statistica 4.0 software package.
3. Results
3.1. Tolerance
The reported side-effects are listed in Table L Nausea 
with or without vomiting was reported by 65% of the 
patients. Often these complaints were unresponsive to
Table 1
Nicotinamide side-effects in 40 patients
Si de-effect No. of patients
Nausea
Vomiting
Flushing
Dizziness
Epigastric pain
Gastrointestinal disturbances
Renal dysfunction
26
13
7
6
3
1
1
Cmax
(nmol/ml)
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1200  -
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400 -
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Fig, 1. Scatterplot of Cniax versus Tmx including all 40 patients.
anti-emetics including ondansetron. Eight patients experi­
enced no side-effects at all while 16 patients had side- 
effects that were considered as severe. Nine patients dis­
continued nicotinamide intake because of side-effects, 
eight because of nausea and one because of renal toxicity. 
Five patients discontinued intake of the drug for other 
reasons: three patients went off study because of very 
poor compliance with the treatment protocol, one patient 
stopped nicotinamide in the fourth week of treatment 
because of the poor taste and dysphagia due to irradia- 
tion-mucositis, and in one case it was decided to stop at 
day 4 because of pre-existent renal disturbances. Of the 16 
patients treated since November 1995, seven had a dose 
reduction to 60 mg/kg because of severe nausea. Only one 
of these 16 patients finally discontinued nicotinamide 
intake because of the side-effects in contrast to eight of 
the 20 patients treated previously (excluding the five 
patients that stopped nicotinamide for other reasons).
There was no indication of an effect of nicotinamide on 
blood pressure or pulse.
3.2. First day nicotinamide plasma profile
Cmax and !Tmax for each individual are shown in Fig. 1. 
Mean and median Cmax were 1154 nmol/ml and 1088 
nmol/ml with a standard deviation (SD) of ±326 nmol/ 
ml and a range of 752-2041 nmol/ml. Thus, in all patients 
a minimal level of 700 nmol/ml could be obtained. Mean 
and median Tmax were 0.83 h and 0.51 h (SD ±0.73 h, range
0.25-3 h). r max was equal or less than 1 h in 33 of the 40 
cases. Fig. 2 illustrates the mean of the pharmacokinetic 
profiles obtained on the first day of treatment of all 40 
patients. The profiles of two individual patients are 
added in the figure to illustrate the inter-individual varia­
bility which is largest during the first hour after nicotina­
mide intake. One patient has a very high Cm;lx with short 
Tmax whereas the other has a relatively low Cmax and long 
Xmax* With the accelerated radiation schedule the second 
treatment of the day is given 7-8 h after nicotinamide
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nic (nmol/m!)
time after nicotinamide intake (hours)
Fig. 2. Nicotinamide plasma concentrations as a function of time after 
intake. Mean of 40 patients with standard deviations. The dotted lines 
represent two individual patients: one with high € mm and short TnYM and 
the other with low Cmax and long Tma7i,
intake at which time the interpolated mean plasma level 
was about 500 nmol/ml. Mean and median Cres were 66 
nmol/ml and 53 nmol/ml (SD ±62 nmol/ml, range 0-221 
nmol/ml).
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Fig. 4. Nicotinamide plasma concentrations at the time of irradiation in 
seven patients. Data obtained before dose reduction (first week), on 3 
consecutive days directly after dose reduction, and during the last week 
of treatment. Different symbols represent different patients (O, patient 
with assumed poor compliance; • ,  patient discontinued nicotinamide 
intake). Dashed horizontal line indicates 700 nmol/ml level.
3.3. Nicotinamide plasma levels during first and last 
weeks of treatment
Fig. 3 shows the individual and mean plasma levels at 
the time of irradiation during the first and last full weeks of 
the treatment. Some patients started radiotherapy on a 
Thursday; in those cases nicotinamide levels were deter­
mined in the first full week but also on the first 2 treatment 
days before and these are also shown in the figure. Nico-
nic (nmol/ml)
first week last week
Fig. 3. Nicotinamide plasma concentrations at the time of irradiation 
during the first and last week of the treatment. Individual values of 40 
patients are represented by the circles. Closed and open symbols repre­
sent values obtained during hospitalisation ( • )  and at the outpatients’ 
department (O). Horizontal bars indicate mean values. Dashed horizontal 
line indicates 700 nmol/ml level.
tinamide levels measured after dose reduction are not 
included. At the start of the treatment 179 of 219 values 
(82%) were above the desired 700 nmol/ml and nine of 40 
patients had lower values more than once. In 11 of 37 
patients a linear least-squares regression fit to the values 
obtained at the time of irradiation during the first full week 
indicated that accumulation of nicotinamide occurred with 
daily administration. In three cases the regression analysis 
could not be carried out because drug intake was already 
discontinued in the first week. Accumulation was not cor­
related with Cres, i.e. patients with a relatively high residual 
24-h level after the first drug dose did not necessarily show 
drug accumulation.
On average, plasma concentrations decreased towards 
the end of the treatment. During the last week 55 of 94 
(59%) values were above the 700 nmol/ml level and nine 
of the 19 patients who continued nicotinamide intake until 
the end of the treatment and without a dose reduction had 
values that fell below this level more than once.
Fig. 4 shows the nicotinamide plasma concentrations for 
the seven patients who had a dose reduction. It includes the 
levels obtained in the first week with doses of 80 mg/kg, 
the levels directly after reduction to 60 mg/kg, and those 
obtained in the last week of the treatment. One patient 
continued having severe side-effects and stopped nicotina­
mide intake. In two patients levels greater than 700 nmol/ 
ml were obtained and reproduced daily with the 60 mg/kg 
dose, three others produced levels in the 400-700 nmol/ml 
range, and in one patient the levels were clearly inadequate 
which, we believe, was largely due to poor compliance. In 
fact this patient had already insufficient levels at the begin­
ning of the treatment.
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Fig. 5. Mean of nicotinamide plasma concentrations measured at the time 
of irradiation during the first week of treatment. Open symbols represent 
mean per patient (35 patients). Patients are divided in two groups by 
severity of nicotinamide side-effects (no-moderate versus severe), 
Closed symbols indicate mean values of the two groups with standard 
deviations.
3.4. Correlation between nicotinamide side-effects and 
plasma levels
Adequate assessment of the severity of side-effects was 
not possible in five cases: three patients were taken out of 
the study because of very poor compliance with the treat­
ment protocol, in one case it was decided to stop at day 4 
because of pre-existing renal disturbances, and in one case 
reporting of side-effects was very inconsistent and unreli­
able and therefore not interpretable. Thus, 35 patients were 
evaluable for this analysis of which 16 patients experi­
enced side-effects that were considered as severe. We 
investigated if the pharmacokinetic parameters could pre­
dict for nicotinamide toxicity by discriminant analysis. 
The following parameters were included: absolute daily 
dose, Cmax, area under the curve (AUC) derived from the 
first day profile, Cres, the mean of the plasma concentra­
tions measured at the time of irradiation during the first 
week (Cmean), and whether or not accumulation occurred. 
There was no correlation between side-effects and abso­
lute daily dose or Cres or AUC, High Cmax (P ~ 0.03) and 
high Cmean (P = 0.008) were correlated with the occur­
rence of severe side-effects. There was a positive correla­
tion between drug accumulation and severe side-effects 
but this did not reach statistical significance (P = 0.10). 
Eight of the 11 patients who showed drug accumulation 
had severe side-effects as compared to seven of the 23 
patients in whom there was no indication of accumulation. 
The most powerful single predictor for severe nicotina­
mide toxicity was Cmean (Fig. 5).
4J. Tolerance
Gastrointestinal symptoms, flushing, dizziness, sweat­
ing, fatigue, and headache were already recognised as 
side-effects of nicotinamide [5,8,9,20], In a previous 
report we associated renal failure with nicotinamide intake 
as a relatively infrequent event but one that can have ser­
ious consequences [11], In our total experience this 
occurred in three of 61 patients that were treated with 
nicotinamide, All three had received nephrotoxic medica­
tion previously (cisplatin) or concomitantly (ACE-inhibi- 
tor, carbasalatcalcium). Consequently we withheld nico­
tinamide in patients with pre-existing renal dysfunction 
and it was not administered concomitantly with nephro­
toxic medication. Since then we have treated 41 other 
patients and no renal toxicity has been observed. One 
patient had a gastric bleeding. He also used carbasalatcal­
cium for analgesia which is a salicylate and known to 
cause gastric irritation which may have been enhanced 
by nicotinamide. One patient reported emotional lability 
and depressive moods. This was also noted in another 
patient treated previously. It remains unclear whether 
this relates to nicotinamide use.
The most frequent adverse effect is nausea with or with­
out vomiting. With prolonged daily administration it 
occurred in 65% of the patients and was often unrespon-
« j
sive to anti-emetics confirming the findings from our pre­
vious study [11]. In 14 patients drug intake was either 
discontinued or the dose was reduced because these symp­
toms were severe and we did not allow these side-effects to 
significantly interfere with nutritional intake as this was 
already impaired in most of our patients. We observed a 
significant correlation between side-effects and some phar­
macokinetic parameters. In particular high plasma concen­
trations over subsequent days are associated with severe 
side-effects whereas absolute daily dose was not. This 
indicates that, apart from direct topical irritation of the 
gastrointestinal mucosa, there is probably also a systemic 
effect. Thus, alternative routes of drug administration may 
not circumvent the problem of nausea.
Severe clinical effects were reported with daily doses 
higher than 6 g or 80 mg/kg administered over a few sub­
sequent days [4,9]. This was associated with high residual 
24-h plasma levels and significant drug accumulation. It 
was suggested that accumulation can become of a particu­
lar concern when residual levels are higher than 300 nmol/ 
ml [9]. With the 80 mg/kg dose we observed relatively low 
residual values after the first drug intake (mean 66 nmol/ 
ml) which did not predict for accumulation or side-effects.
4 2 . Cmax and Tm<.ax
The nicotinamide plasma profiles obtained on the first 
treatment day show that, with a dose of 80 mg/kg, ade-
72 J.H.AM. Kaanders et al. /  Radiotherapy and Oncology 43 (1997) 67-73
quate (>700 nmol/ml) levels could be obtained in all 
patients. Large inter-patient variations in Cmax were seen 
however. We used a liquid formulation which, on average, 
produced higher peak levels than tablets which were used 
in other studies [9,19] and also shorter Timx with a mean of
0.83 h (SD ±0.73) as compared to 2.1 h (SD ±L3) with 
tablets [9]. Apparently the drug is more rapidly absorbed 
when administered as a liquid formulation resulting in 
higher Cmax. Initially, irradiations were given 1.5 h after 
drug intake but when an interim-analysis showed this short 
r max, the interval was reduced to 1 h. Eighty-three per cent 
(33/40) of the patients had Timx < 1 h and the inter-patient 
variability was less than with tablets which can be of 
advantage for the timing of irradiations. It has been sug­
gested that absorption is also more rapid with higher peak 
concentrations when the drug is taken on an empty sto­
mach [8,9]. Our patients were allowed to take a light meal 
at least 1 h before drug intake* We found it not advisable 
for them to skip or postpone meals as most have impaired 
nutritional intake because of the location of the tumour 
and, as treatment progresses, because of radiation muco­
sitis.
43, Compliance
On the first 2 treatment days, when patients were hos­
pitalised and nicotinamide was ingested in the presence of 
the nurse who was to obtain the plasma sample, nicotina­
mide levels at the time of irradiation were nearly always 
adequate. With progression of treatment there was an 
increasing proportion of values below 700 nmol/ml with 
some being very low or even zero. During the last week of 
the treatment nine of the 19 patients who continued nico­
tinamide intake until the end of the treatment and without a 
dose reduction had repeatedly low values at the time of 
irradiation. In some but not all cases this could be 
explained because the patient vomited shortly after nico­
tinamide intake. Alternatively, repeated administration of 
nicotinamide might possibly activate metabolic pathways 
resulting in a more rapid elimination of the drug. However, 
full kinetic profiles obtained in patients administered the 
same dose of nicotinamide daily, albeit over 12 days, 
showed no indication of this [9], Furthermore, together 
with nicotinamide concentrations, we measured the 
plasma levels of the three major metabolites of nicotina­
mide (1-methyl nicotinamide, nicotinamide N-oxide, and 
2-pyridones) in our patients at the start of treatment and 5 -
7 weeks later (data not shown). The metabolite levels gave 
no indication of a faster elimination of the drug with time,
1.e. low levels of nicotinamide correspond with low levels 
of metabolites. We must therefore assume a decreased 
compliance, i.e. patients were not always taking the dose 
of nicotinamide they were supposed to. This may well be 
caused by the experience of side-effects and the bad taste 
which is a disadvantage of the liquid formulation. An 
additional argument is the often weak psychosocial status
of head and neck cancer patients with inadequate self-care 
including poor drug compliance. Other patient categories 
may do better in this respect.
4.4, Dose reduction
i
The high mean plasma concentrations shown in Fig. 5 
suggest that a moderate dose reduction for those patients 
with severe adverse effects might still produce adequate 
plasma levels. All but one had mean plasma levels greater 
than 900 nmol/ml at the time, of iiTadiations. It was shown 
that peak plasma levels are linearly dependent on the 
administered drug dose [8,18,19]. If levels of at least 
900 nmol/ml can be obtained with 80 mg/kg, the expected 
minimum level after a 25% reduction of dose would be 
around 700 nmol/ml or slightly lower. We introduced a 
dose reduction to 60 mg/kg for patients who experienced 
severe nausea and/or intractable vomiting. Tolerance 
improved after this moderate reduction of dose in six of 
seven patients and they were able to continue nicotinamide 
intake until the end of the treatment. In five patients indeed 
plasma concentrations of about 75% of the initial values 
were obtained on some days but in only two patients this 
could be reproduced daily. This is probably not attributa­
ble to the reduced drug dose only but also to a reduced 
compliance as was argued above. Possibly, when the lower 
dose is administered from the start of treatment, better 
tolerance may also lead to improved compliance.
In rodent tumours, nicotinamide plasma levels between 
700-1000 nmol/ml achieve significant increases in radio­
sensitization over that of carbogen alone [14]. In this cur­
rent study we have demonstrated that these levels can be 
achieved in man with oral doses of 80 mg/kg but it is not 
always possible to reproduce such levels daily during a 
fractionated radiation treatment. Lower doses may 
improve tolerance and compliance but the question arises 
whether such doses can produce drug levels sufficient for 
significant radiosensitization. Further studies in experi­
mental tumours are needed to determine the lower thresh­
old dose for radiosensitization by nicotinamide. It may 
also be helpful to obtain a pharmacokinetic profile from 
each patient over the first 2 h after nicotinamide intake 
prior to the start of treatment for optimal timing such 
that patients are irradiated as close to their individual 
Tmax as possible. It has been shown that, with repeated 
drug administrations, the intra-patient variations of Tmax 
are small [9].
5. Conclusions
A nicotinamide dose of 80 mg/kg administered as a 
liquid formulation can produce peak plasma concentra­
tions above the 700 nmol/ml level in all patients. Equiva­
lent levels have been shown to be sufficient for 
radiosensitization in mice. However, due to adverse
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effects and loss of compliance, these concentrations could 
not be reproduced during the full course of the 5- to 7- 
week treatment in a significant portion of the subjects. 
High plasma concentrations over subsequent days are 
associated with severe side-effects and a 25% dose reduc­
tion can improve tolerance. The question remains whether 
drug concentrations obtained after such dose reduction are 
still effective. Timing of irradiations may become more 
critical with the lower dose and further studies are needed 
to assess the threshold dose for radiosensitization by nico­
tinamide.
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